NVAX - Novavax, Inc.
| Previous Close | 1.89 |
| Open | 1.90 |
| Bid | 1.87 x 1000 |
| Ask | 1.88 x 1000 |
| Day's Range | 1.78 - 1.92 |
| 52 Week Range | 0.96 - 2.75 |
| Volume | 2,848,356 |
| Avg. Volume | 5,688,945 |
| Market Cap | 719.273M |
| Beta (3Y Monthly) | 3.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.56 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.67 |
- ACCESSWIRE•7 days ago
Novavax Shares Gain as its Lead Compounds Move Forward, Analysts Review and Target
NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Novavax, Inc. (NVAX), a biotechnology company focused on the discovery and development of innovative vaccines to prevent serious respiratory diseases. The company's products are targeted for worldwide markets and its core commercial team is already laying the groundwork before launching with government policymakers, provider, payers, associations, advocates and opinion leaders in advance of regulatory approval.
- Motley Fool•8 days ago
3 Top Small-Cap Stocks to Buy in October
Big rewards can be found in small packages.
- Investopedia•12 days ago
Top 3 Healthcare Penny Stocks for 2018
The healthcare industry can be precarious for stocks of large companies, much less penny stocks. None of these are new companies – they have made progress in developing products and finding the marketing outlets that are needed to sustain them. Because of the higher risk, investors should continuously perform due diligence.
- Motley Fool•12 days ago
Here's Why Novavax Gained 20.5% in September
A Wall Street analyst turned bullish -- and the market responded in kind. But investors may want to consider the binary nature of this biopharma stock.
- ACCESSWIRE•12 days ago
Major Biotech Announcements Moving the Market
HENDERSON, NV / ACCESSWIRE / October 10, 2018 / The biotech market is moved by events and announcements. There are a few major events currently impacting the companies highlighted below. Propanc Biopharma, ...
Market Realist•13 days agoNovavax’s ResVax Vaccine Could Be Blockbuster Market Opportunity
According to Novavax’s Q2 2018 earnings conference call, ~3.9 million babies are born annually in the United States. About 70% of them are afflicted with RSV (respiratory syncytial virus) before the age of one year. Novavax (NVAX) thus expects all infants up to six months of age to be exposed to RSV.
Motley Fool•13 days ago3 Top Small-Cap Stocks to Buy in October
These investors think Greenbrier, Novavax, and Winnebago will help keep the small-cap rally running.
- Market Realist•14 days ago
ResVax Vaccine Program Is Novavax’s Key Growth Driver in 2018
Based on this progress, Novavax expects to release final efficacy data in the first quarter of 2019. According to Novavax’s second-quarter 2018 earnings conference call, since the FDA has granted fast-track designation to the ResVax program, the company becomes eligible for priority review of its BLA. The above diagram is a snapshot of Novavax’s investor presentation, which shows that 85% or more of infant hospitalizations could have been prevented if they had been immunized with the RSV (respiratory syncytial virus) vaccine.
Market Realist•14 days agoNovavax Expected to Report Solid Revenue Growth in Fiscal 2018
Novavax (NVAX) has reported 2018 YTD (year-to-date) returns of 70.16%. In the second quarter of 2018, Novavax reported revenues of $10.78 million, which is a YoY rise of 60.2%. According to a Novavax investor presentation, RSV (respiratory syncytial virus) infection is the second leading cause of death globally in children younger than one year of age, just behind malaria.
- Market Realist•14 days ago
Here’s How Novavax Stock Is Moving in the First Week of October
Novavax (NVAX) is a clinical stage biotechnology company focused on the development of vaccines targeting infectious diseases with significant unmet demand. The stock rose 11.29%, from $1.86 on October 1 to $2.07 on October 5, mainly due to updates to the company’s research pipeline at the Ladenburg Thalmann 2018 Healthcare Conference on October 2 and the 2018 Cantor Global Healthcare Conference n October 3. Novavax is currently trading 115.22% higher than its 52-week low of $0.96 and 24.73% lower than its 52-week high of $2.75.
- Benzinga•14 days ago
FBR: Novavax Looks Healthy Ahead Of Catalysts
As Novavax, Inc. (NASDAQ: NVAX ) approaches two key dates in its pipeline, bulls are preparing to profit. The Rating B Riley FBR analysts George Zavoico and Dylan Dupuis maintained a Buy rating on Novavax ...
- Zacks•18 days ago
Do Options Traders Know Something About Novavax (NVAX) Stock We Don't?
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
- ACCESSWIRE•18 days ago
Today's Research Reports on Trending Tickers: Amarin and Novavax
NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Major U.S. markets closed up on Wednesday, with the Dow Jones hitting a record high for the 15th time this year on upbeat economic data. However, market gains ...
- GlobeNewswire•20 days ago
Novavax to Highlight RSV Program Data at Two Upcoming Meetings
GAITHERSBURG, Md., Oct. 02, 2018 -- Novavax, Inc. (NASDAQ: NVAX) today announced that its representatives will share data from its RSV F vaccine program via oral and poster.
- Motley Fool•22 days ago
Better Buy: Novavax, Inc. vs. Pfizer Inc.
Which stock wins in a matchup between an up-and-coming biotech and a longtime big pharma winner?
- GlobeNewswire•26 days ago
Novavax to Present at Two Upcoming Investor Conferences
GAITHERSBURG, Md., Sept. 26, 2018-- Novavax, Inc. today announced that it will present at the Ladenburg Thalmann 2018 Healthcare Conference and the Cantor Global Healthcare Conference 2018, both in the ...
- Zacks•26 days ago
Novavax (NVAX) Catches Eye: Stock Jumps 7.6%
Novavax (NVAX) shares rose nearly 8% in the last trading session, amid huge volumes.
Market Realist•27 days agoAnalysts See a Strong Upside in Novavax Stock
In September 2018, of the total eight analysts covering Novavax (NVAX), five analysts have given Novavax stock a “buy” or higher rating, and three analysts have given Novavax a “hold” rating. The mean rating for Novavax stock is 2.13 with a target price of $3.86, implying an upside potential of 141.3% over Novavax’s closing price of $1.60 as of September 21.
- Market Realist•27 days ago
Why Novavax Is Keeping Investors Excited in 2018
The company is a clinical stage biotechnology company with a focus on recombinant nanoparticle vaccines and adjuvants. Novavax’s product pipeline is mainly focused on respiratory syncytial virus (or RSV) and seasonal influenza. Its RSV programs are targeted at three different populations: older adults, pediatrics, and infants via maternal immunization.
Market Realist•27 days agoAnalyzing Novavax’s Operational Performance
Novavax (NVAX) incurred general and administrative expenses of $8.22 million in the second quarter of 2018 as compared with $8.94 million in the second quarter of 2017. Novavax’s operating loss was $41.99 million in the second quarter of 2018 as compared with an operating loss of $41.47 million in the second quarter of 2017. Novavax’s interest expense was relatively flat at $3.4 million in the second quarter of 2018 as compared with $3.52 million in the second quarter of 2017.
- GlobeNewswire•27 days ago
Novavax Initiates Phase 2 Clinical Trial of NanoFlu™ in Older Adults
Novavax, Inc. (NVAX) today announced the initiation of a Phase 2 dose and formulation confirmation clinical trial in older adults of NanoFlu, its nanoparticle seasonal influenza vaccine candidate. “Initiating this Phase 2 clinical trial of NanoFlu is an important milestone for Novavax,” said Stanley C. Erck, President and Chief Executive Officer of Novavax.
- Motley Fool•28 days ago
Why Novavax Inc. Is Surging 14.4% Higher Today
Investor interest is perking up following bullish comments on Friday.
- Motley Fool•last month
Why Transocean, Novavax, and Steelcase Jumped Today
Find out what left these stocks looking more energetic.
- Benzinga•last month
ResVax, NanoFlu Prospects Earn Novavax A Double Upgrade
Novavax, Inc. (NASDAQ: NVAX ) has fallen 31 percent over the last six months, mirroring waning investor excitement over a coming pivotal trial. Amid the heavy sell-off, one analyst sees a buying opportunity ...
- MarketWatch•last month
Novavax's stock soars after J.P. Morgan swings to bullish from bearish ahead of trial results
Shares of Novavax Inc. soared 12% in premarket trade Friday, after J.P. Morgan analyst Eric Joseph swung to bullish from bearish, citing a favorable risk-reward investment profile ahead of pivotal trial data on its RSV treatment for infants, due out in the first quarter of 2019. Joseph raised his rating two notches to overweight from underweight. He said the shares have already pulled back sharply from recent highs on "receding expectations" regarding the trial outcome. As a result, he sees 50% to over 100% potential upside in the stock after the results, and about an 80% downside risk on a trial failure, but that is viewed as a "less likely" event. "Looking beyond the phase 3 readout, we believe positive PREPARE data would support broader development to additional at-risk populations and their inclusion in the model (pediatric patients under 2yo)," Joseph wrote in a note to clients. The stock had tumbled 39% from the Feb. 20 17-month closing high of $2.42. Over the same time, the iShares Nasdaq Biotechnology ETF has climbed 9.2% and the S&P 500 has advanced 7.9%.
